1.Real-world use of tolvaptan in hyponatremia: A single-centre experience
Fei Bing Yong ; Nur Hidayah Mohd Makhatar ; Siew Wai Shuit ; Shamharini Nagaratnam ; Zanariah Hussein
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):12-
Introduction:
Hyponatremia is the most common electrolyte imbalance in hospitalized patients, associated with increased morbidity
and mortality. Tolvaptan effectively raises serum sodium in SIADH. However, concerns regarding rapid overcorrection
and safety persist. This study evaluates the efficacy, safety, and real-world usage patterns of tolvaptan in a tertiary care
setting.
Methodology:
A retrospective single-centre observational study was conducted at Hospital Putrajaya using the electronic records of
patients treated with tolvaptan from January 2020 to December 2025. Overcorrection was defined as >10 mmol/L increase
within 24 hours, and non-response as <4 mmol/L increment at 24 hours.
Results:
Twenty-one patients were included, with a mean age of 66.7 years; 57% were male. Most (90.5%) received 7.5 mg initially.
Mean baseline sodium was 118.1 ± 4.1 mmol/L. Tolvaptan produced rapid correction, with mean sodium increasing to
127.0 mmol/L at 24 hours (mean increment 8.9 mmol/L). Only one patient (4.8%) was a non-responder at 24 hours. Median
time to sodium >130 mmol/L was 1 day, with 60% achieving this within 24 hours. At discharge, mean sodium was 130.4
mmol/L. Median length of stay following initiation was 5.5 days. Overcorrection occurred in 23.8% (n = 5), all in the 7.5
mg group, particularly among those with baseline sodium 115–120 mmol/L. No cases of osmotic demyelination syndrome
(ODS) were observed. The mean internal for initiation is approximately 6 days from diagnosis. Tolvaptan usage increased
and peaked in the first 3 years, but subsequently dropped and plateaued over the last 2 years.
Conclusion
Tolvaptan is safe and effective for sodium correction; although overcorrection remains a risk, no long-term sequelae of
ODS were observed, underscoring the need for vigilant monitoring. Its use in Hospital Putrajaya remains limited, with
delayed initiation possibly due to tolvaptan being considered a secondary treatment after failure of other options
Hyponatremia
;
Tolvaptan
2.Single-stage adrenalectomy and hysterectomy for pheochromocytoma with giant uterine fibroid: A multidisciplinary perioperative challenge
Fei Bing Yong ; Sarojini Devi Simanchalam ; Hidayatil Alimi Keya Nordin ; Nithiya Devi Kandasami ; Sadhana Sadar Mahamad ; Suhaimi Jaafar ; Mohd Wajdi Zanuddin ; Poh Shean Wong ; Chin Voon Tong ; Noor Lita Adam ; Zanariah Hussein
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):20-
Introduction:
Pheochromocytoma is a catecholamine-secreting adrenal
tumor associated with major perioperative hemodynamic
instability. When concurrent major pelvic pathology
requires surgery, operative planning becomes particularly
challenging. We describe the successful single-stage
management of pheochromocytoma and a giant uterine
fibroid, highlighting the importance of multidisciplinary
coordination and perioperative optimization.
Case:
A 49-year-old female with symptomatic uterine fibroid
was found to have proliferative endometrium on a pipelle
biopsy. Computed tomography (CT) abdomen incidentally
detected a right adrenal mass alongside a large posterior
uterine fibroid (11.9 × 17.4 × 14.6 cm). CT adrenal protocol
demonstrated a heterogeneously enhancing right adrenal
mass (6.9 × 6.9 × 9.6 cm) with high unenhanced attenuation.
Biochemical evaluation revealed markedly elevated
24-hour urinary metanephrine (4.7× upper limit) and
normetanephrine (2.4× upper limit).
Following multidisciplinary discussions, a single-stage
surgical approach was planned after careful assessment of
feasibility and perioperative risk in view of the uncertain malignant potential of the pelvic mass and to minimize
repeated exposure to anesthesia. Preoperative optimization
included transitioning from terazosin to phenoxybenzamine, with subsequent addition of bisoprolol for
hemodynamic control. The operative strategy prioritized
pheochromocytoma resection first, given its potential
for significant hemodynamic instability. Progression to
hysterectomy was contingent upon achieving adequate
intraoperative hemodynamic stability following adrenalectomy, with continuous reassessment by the anesthetic
and surgical teams.
Right adrenalectomy was performed first, followed by
total abdominal hysterectomy with bilateral salpingooophorectomy. Significant hemodynamic lability occurred
during tumor manipulation, with hypertensive surges
managed using sodium nitroprusside and remifentanil
infusions. Following adrenal vein ligation and tumor
removal, hypotension was managed with noradrenaline
and additional adrenaline support as required. Total
operative time was approximately 6 hours. Postoperatively,
transient noradrenaline support was required but was
rapidly weaned as hemodynamic stability was achieved.
Conclusion
Single-stage adrenalectomy and major pelvic surgery
can be safely performed in selected patients with pheochromocytoma when guided by meticulous preoperative
optimization, clear intraoperative sequencing, and close
multidisciplinary coordination.
Pheochromocytoma
;
Adrenalectomy
;
Leiomyoma
;
Hysterectomy
3.Efficacy and Safety of SGLT2 Inhibitors in Elderly (≥75 Years) With Type 2 Diabetes: A Real-World Study
Siew Wai Shuit ; Shamharini Nagaratnam ; Fei Bing Yong ; Norisha Nandini Passkaren ; Keen Tien Boey ; Nur Syahirah Asarapoo ; Sathya Rajagopal ; Vikganesa Mahalingam ; Zanariah Hussein
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):36-
Introduction:
Sodium-glucose-linked-transporter inhibitors (SGLT2-i)
have demonstrated cardiovascular and renal benefits in
type 2 diabetes mellitus (T2DM), but patients aged ≥75
years remain underrepresented in major trials, creating
uncertainty regarding their risk–benefit profile. Real-world
data show mixed safety signals. In Malaysia, local evidence
is limited despite a growing elderly diabetic population.
This study evaluates the glycemic efficacy and safety of
SGLT2-i in advanced elderly patients in a real-world public
hospital setting.
Methodology:
We conducted a retrospective observational cohort study
of patients aged ≥75 years with T2DM initiated on SGLT2-i
in Hospital Putrajaya (2020–2024). Electronic records were
reviewed for demographics, comorbidities, medications,
and biochemical parameters. Outcomes at 6–12 months
assessed glycemic control and safety. Adverse events
and discontinuation rates were recorded. Patients with
incomplete data, type 1 diabetes, active malignancy, or
severe renal impairment were excluded.
Results:
A total of 104 patients (mean age 78.2 years; 54% female)
were included with a high proportion (76.9%) classified as at
high cardiovascular risk due to established macrovascular
disease (57.7%) or nephropathy (53.8%). Indications for
SGLT2-i initiation were glycemic control alone (69.2%) and
together with cardiorenal protection (58.7%). Glycemic
control remained stable (hemoglobin A1c: 7.66–7.45%; p =
0.076), with preserved renal function (estimated glomerular
filtration rate: 58.65–58.11 mL/min/1.73 m²; p = 0.575).
Overall safety was favorable, with 90.4% experiencing no
adverse events. Minor adverse events included urinary
tract infections (2.9%) and polyuria (1.9%). ASCVD-related
hospitalizations occurred in 4.8% of patients, with a low
discontinuation rate (7.7%). A statistically significant
weight reduction was observed (baseline 66.67 kg, −1.01
kg; p = 0.005) but was not clinically significant. Proteinuria
improvement was noted in 15.7% of patients.
Conclusion
SGLT2-i are safe and well-tolerated in elderly T2DM
patients (≥75 years), with stable glycemic control, preserved
renal function, and minimal adverse events, supporting
their use in very elderly Asian populations.
Aged
;
Diabetes Mellitus, Type 2
;
Sodium-Glucose Transporter 2 Inhibitors
4.Cushing Disease Masquerading as Polycystic Ovary Syndrome: A Diagnostic Pitfall in Severe Hyperandrogenism
Jean Mun Cheah ; Fei Bing Yong ; K.J. Lingeswary ; Jen Hoong Oon ; Sharifah Noor Adrilla binti Long Mohd Noor Affendi ; Gayathri Devi A/P Krishnan ; Shazatul Reza binti Mohd Redzuan ; Subashini Rajoo Rajoo
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):97-
Introduction:
Polycystic ovary syndrome (PCOS) is the most common
cause of hyperandrogenism in women of reproductive
age. However, several endocrine disorders, particularly
Cushing disease (CD), can closely mimic the clinical, biochemical, and radiological features of PCOS. This overlap
may lead to misdiagnosis and delayed recognition of
hypercortisolism, with significant metabolic and reproductive consequences.
Case:
We report a 24-year-old female with young-onset diabetes
mellitus who was referred for endocrine co-management
during admission for recurrent mons pubis and labial
abscesses with poorly controlled glycemia. She had a 5-year
history of progressive hirsutism, oligomenorrhoea, scalp
hair loss, significant weight gain, and insulin resistance,
and had previously been labelled as having PCOS during
adolescence, with subsequent default of follow-up. On
examination, she was obese (body mass index 33 kg/
m²) with plethoric facies, acanthosis nigricans, proximal
myopathy, and hirsutism (Ferriman–Gallwey score 10),
without overt virilization or acromegalic features.
Biochemical evaluation demonstrated severe hyperandrogenism with markedly elevated total testosterone
(7.05 nmol/L), suppressed gonadotropins, and adrenocorticotropic hormone (ACTH)-dependent hypercortisolism. Cortisol failed to suppress on low-dose dexamethasone testing, and 24-hour urinary free cortisol
was markedly elevated (>4,900 nmol/24 h). Pelvic ultrasonography and computed tomography imaging showed
polycystic ovarian morphology without evidence of an
ovarian mass. Pituitary magnetic resonance imaging
revealed a small right-sided pituitary microadenoma
measuring 2.6 × 3.7 mm. Inferior petrosal sinus sampling
demonstrated a central-to-peripheral ACTH gradient with
adequate prolactin ratios, confirming pituitary CD.
Conclusion
This case highlights how Cushing disease can closely
mimic PCOS, including polycystic ovarian morphology
and hyperandrogenism. Progressive symptoms, severe
biochemical androgen excess, and marked insulin
resistance should prompt evaluation for secondary causes
of hyperandrogenism, particularly hypercortisolism, to
avoid delayed diagnosis and prolonged morbidity.
Female
;
Hyperandrogenism
;
Pituitary ACTH Hypersecretion
;
Polycystic Ovary Syndrome
5.Biochemical Discordance in Acromegaly Complicated by Pituitary Apoplexy and Severe Insulin Resistance
Jean Mun Cheah ; Fei Bing Yong ; K.J. Lingeswary ; Jen Hoong Oon ; Sharifah Noor Adrilla binti Long Mohd Noor Affendi ; Gayathri Devi A/P Krishnan ; Shazatul Reza binti Mohd Redzuan ; Subashini Rajoo
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):100-
Introduction:
Acromegaly is usually diagnosed by elevated age- and
sex-adjusted insulin-like growth factor-1 (IGF-1) levels
reflecting chronic growth hormone (GH) excess. IGF-1 is
preferred as a screening biomarker due to its longer half-life
and reduced pulsatility compared with GH. However, IGF1 levels may be disproportionately low or only modestly
elevated in certain clinical contexts, leading to diagnostic
uncertainty. Pituitary apoplexy is one such condition in
which acute tumor hemorrhage or infarction may disrupt
sustained GH secretion and attenuate IGF-1 production
Case:
A 48-year-old female with hypertension, type 2 diabetes
mellitus, and dyslipidemia presented with a 2-day history
of severe headache, vomiting, and visual disturbance, on a
background of progressive acral enlargement over 2 years.
Examination revealed coarse facial features, prognathism,
enlarged hands, and cranial nerve involvement. Magnetic
resonance imaging demonstrated an invasive sellar–
suprasellar pituitary macroadenoma with optic chiasmal
compression and cavernous sinus encasement. Intravenous
dexamethasone was initiated pre-operatively due to a
significant mass effect.
Biochemical evaluation showed markedly elevated
random GH levels (>50 ng/mL) with only mildly elevated
IGF-1 at 1.19 times the upper limit of normal, below the
threshold at which confirmatory oral glucose tolerance
testing may be omitted according to current guidelines.
Other pituitary axes suggested evolving hypopituitarism.
During admission, she developed severe hyperglycemia
with marked insulin resistance, requiring high-dose insulin
therapy (approximately 1.5 U/kg/day). She underwent
urgent transsphenoidal surgery, with histopathology
confirming a pituitary neuroendocrine tumor with extensive
hemorrhage and infarction, consistent with pituitary
apoplexy. Postoperatively, GH levels were suppressed to
<5 ng/mL, insulin requirements decreased markedly, and
hormone replacement was initiated for secondary adrenal
insufficiency and central hypothyroidism.
Conclusion
This case highlights that IGF-1 levels below conventional
diagnostic thresholds do not exclude clinically significant
acromegaly, particularly in the setting of pituitary
apoplexy. Integration of clinical phenotype, GH levels, and
imaging findings is essential to avoid diagnostic delay and
ensure timely management.
Acromegaly
;
Insulin Resistance
;
Pituitary Apoplexy
6.Hyperthyroidism and Gestational Trophoblastic Disease: A Case Report
K.J. Lingeswary ; Jean Mun Cheah ; Fei Bing Yong ; Jen Hoong Oon ; Aniqah Shamimi ; Sharifah Noor Adrilla binti Long Mohd Noor Affendi ; Gayathri Devi A/P Krishnan ; Shazatul Reza Binti Mohd Redzuan ; Subashini Rajoo
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):118-119
Introduction:
Gestational trophoblastic disease (GTD) is an uncommon
but important cause of secondary hyperthyroidism,
termed trophoblastic hyperthyroidism, resulting from
the structural similarity between human chorionic
gonadotropin (hCG) and thyroid-stimulating hormone
(TSH). Excessively elevated hCG levels can stimulate
the TSH receptor, leading to increased thyroid hormone
production and clinically significant thyrotoxicosis. Early
recognition is essential as uncontrolled hyperthyroidism
may lead to serious perioperative complications.
Case:
We report a 50-year-old female who presented with
persistent vaginal bleeding following a prior uterine
evacuation. Clinical examination and ultrasonography
revealed a uterine mass corresponding to approximately
14 weeks’ gestation. Serum β-hCG was markedly elevated
at >1,000,000 IU/L. Histopathological evaluation confirmed
choriocarcinoma. Thyroid function tests demonstrated
severe biochemical hyperthyroidism, with suppressed TSH
and elevated free thyroxine levels. Notably, the patient did
not exhibit classic symptoms or signs of hyperthyroidism
such as palpitations, tremor, goiter, or thyroid eye signs.
She was started on beta-blockers and carbimazole for initial control. Given the underlying pathology, early definitive
surgical management was planned with multidisciplinary
input, and she subsequently underwent total abdominal
hysterectomy with bilateral salpingo-oophorectomy
successfully.
Hyperthyroidism in GTD is well described, but patients
may remain clinically asymptomatic despite significant
biochemical derangement, as seen in this case. Markedly
elevated β-hCG can mimic primary thyroid disease and
may lead to misinterpretation if the underlying cause is not
recognized. While antithyroid drugs such as carbimazole
are commonly initiated, they may have limited effect in
this setting, as the hyperthyroidism is driven by hCG rather
than intrinsic thyroid overactivity. Beta-blockers play an
important role in controlling symptoms and reducing
peripheral conversion of T4–T3. Early definitive treatment
of the underlying trophoblastic disease remains the key
to resolution.
Conclusion
Trophoblastic hyperthyroidism is a reversible condition
secondary to the underlying disease process. Treatment
of the trophoblastic tumor results in resolution of the
thyrotoxic state. Early recognition and appropriate
preoperative optimization are essential to ensure safe
patient outcomes.
Gestational Trophoblastic Disease
;
Hyperthyroidism
7.Guideline for Adult Weight Management in China
Weiqing WANG ; Qin WAN ; Jianhua MA ; Guang WANG ; Yufan WANG ; Guixia WANG ; Yongquan SHI ; Tingjun YE ; Xiaoguang SHI ; Jian KUANG ; Bo FENG ; Xiuyan FENG ; Guang NING ; Yiming MU ; Hongyu KUANG ; Xiaoping XING ; Chunli PIAO ; Xingbo CHENG ; Zhifeng CHENG ; Yufang BI ; Yan BI ; Wenshan LYU ; Dalong ZHU ; Cuiyan ZHU ; Wei ZHU ; Fei HUA ; Fei XIANG ; Shuang YAN ; Zilin SUN ; Yadong SUN ; Liqin SUN ; Luying SUN ; Li YAN ; Yanbing LI ; Hong LI ; Shu LI ; Ling LI ; Yiming LI ; Chenzhong LI ; Hua YANG ; Jinkui YANG ; Ling YANG ; Ying YANG ; Tao YANG ; Xiao YANG ; Xinhua XIAO ; Dan WU ; Jinsong KUANG ; Lanjie HE ; Wei GU ; Jie SHEN ; Yongfeng SONG ; Qiao ZHANG ; Hong ZHANG ; Yuwei ZHANG ; Junqing ZHANG ; Xianfeng ZHANG ; Miao ZHANG ; Yifei ZHANG ; Yingli LU ; Hong CHEN ; Li CHEN ; Bing CHEN ; Shihong CHEN ; Guiyan CHEN ; Haibing CHEN ; Lei CHEN ; Yanyan CHEN ; Genben CHEN ; Yikun ZHOU ; Xianghai ZHOU ; Qiang ZHOU ; Jiaqiang ZHOU ; Hongting ZHENG ; Zhongyan SHAN ; Jiajun ZHAO ; Dong ZHAO ; Ji HU ; Jiang HU ; Xinguo HOU ; Bimin SHI ; Tianpei HONG ; Mingxia YUAN ; Weibo XIA ; Xuejiang GU ; Yong XU ; Shuguang PANG ; Tianshu GAO ; Zuhua GAO ; Xiaohui GUO ; Hongyi CAO ; Mingfeng CAO ; Xiaopei CAO ; Jing MA ; Bin LU ; Zhen LIANG ; Jun LIANG ; Min LONG ; Yongde PENG ; Jin LU ; Hongyun LU ; Yan LU ; Chunping ZENG ; Binhong WEN ; Xueyong LOU ; Qingbo GUAN ; Lin LIAO ; Xin LIAO ; Ping XIONG ; Yaoming XUE
Chinese Journal of Endocrinology and Metabolism 2025;41(11):891-907
Body weight abnormalities, including overweight, obesity, and underweight, have become a dual public health challenge in Chinese adults: overweight and obesity lead to a variety of chronic complications, while underweight increases the risks of malnutrition, sarcopenia, and organ dysfunction. To systematically address these issues, multidisciplinary experts in endocrinology, sports science, nutrition, and psychiatry from various regions have held multiple weight management seminars. Based on the latest epidemiological data and clinical evidence, they expanded the guideline to include assessment and intervention strategies for underweight, in addition to the core content of obesity management. This guideline outlines the etiological mechanisms, evaluation methods, and multidimensional management strategies for overweight and obesity, covering key areas such as diagnosis and assessment, medical nutrition therapy, exercise prescription, pharmacological intervention, and psychological support. It is intended to provide a scientific and standardized approach to weight management across the adult population, aiming to curb the rising prevalence of obesity, mitigate complications associated with abnormal body weight, and improve nutritional status and overall quality of life.
8.Guideline for diagnosis and treatment of infection after internal fixation of closed lower limb fractures in adults (version 2025)
Bobin MI ; Faqi CAO ; Weixian HU ; Wu ZHOU ; Chenchen YAN ; Hui LI ; Yun SUN ; Yuan XIONG ; Jinmi ZHAO ; Qikai HUA ; Xinbao WU ; Xieyuan JIANG ; Dianying ZHANG ; Zhongguo FU ; Dankai WU ; Guangyao LIU ; Guodong LIU ; Tengbo YU ; Jinhai TAN ; Xi CHEN ; Fengfei LIN ; Zhangyuan LIN ; Dongfa LIAO ; Aiguo WANG ; Shiwu DONG ; Gaoxing LUO ; Zhao XIE ; Dong SUN ; Dehao FU ; Yunfeng CHEN ; Changqing ZHANG ; Kun LIU ; Deye SONG ; Yongjun RUI ; Fei WU ; Ximing LIU ; Junwen WANG ; Meng ZHAO ; Biao CHE ; Bing HU ; Chengjian HE ; Guanglin WANG ; Xiao CHEN ; Guandong DAI ; Shiyuan FANG ; Wenchao SONG ; Ming CHEN ; Guanghua GUO ; Yongqing XU ; Lei YANG ; Wenqian ZHANG ; Kun ZHANG ; Xin TANG ; Hua CHEN ; Weiguo XU ; Shuquan GUO ; Yong LIU ; Xiaodong GUO ; Zhewei YE ; Liming XIONG ; Tian XIA ; Hongbin WU ; Qisheng ZHOU ; Mengfei LIU ; Yiqiang HU ; Yanjiu HAN ; Hang XUE ; Kangkang ZHA ; Wei CHEN ; Zhiyong HOU ; Bin YU ; Jiacan SU ; Peifu TANG ; Baoguo JIANG ; Guohui LIU
Chinese Journal of Trauma 2025;41(5):421-432
Postoperative infection of internal fixation of closed fractures the lower limbs in adults represents a devastating complication, characterized by diagnostic challenges, prolonged treatment duration and high disability rates. Current management of these infections faces multiple challenges, such as difficulties in early accurate diagnosis, and various controversies about the treatment plan, leading to poor overall diagnosis and treatment results. To address these issues, based on evidence-based medicine and principles with emphasis on scientific rigor, clinical applicability and innovation, the Trauma Branch of the Chinese Medical Association, Orthopedic Branch of the Chinese Medical Doctor Association, Orthopedics Branch of the Chinese Medical Association, and Trauma Orthopedics and Polytrauma Group of the Resuscitation and Emergency Committee of the Chinese Medical Doctor Association have collaboratively organized a panel of relevant experts to develop the Guideline for diagnosis and treatment of infection after internal fixation of closed lower limb fractures in adults ( version 2025). The guideline proposed 10 recommendations, aiming to provide a foundation for standardized diagnosis and treatment of postoperative infection in adults with closed lower limb fractures.
9.Guideline for the diagnosis and treatment of vertebral refracture after percutaneous vertebral augmentation in elderly patients with osteoporotic thoracolumbar compression fractures (version 2025)
Yong YANG ; Xiaoguang ZHOU ; Qixin CHEN ; Jian CHEN ; Jian DONG ; Liangjie DU ; Shunwu FAN ; Jin FAN ; Zhong FANG ; Haoyu FENG ; Shiqing FENG ; Haishan GUAN ; Aiguo GAO ; Yanzheng GAO ; Yong HAI ; Da HE ; Dengwei HE ; Haiyi HE ; Dianming JIANG ; Xuewen KANG ; Bin LIN ; Baoge LIU ; Changqing LI ; Fang LI ; Li LI ; Fangcai LI ; Weishi LI ; Xiaoguang LIU ; Hongjian LIU ; Xinyu LIU ; Yong LIU ; Zhongjun LIU ; Shibao LU ; Xuhua LU ; Fei LUO ; Yuhai MA ; Keya MAO ; Xuexiao MA ; Bin MENG ; Xu NING ; Limin RONG ; Hongxun SANG ; Jun SHU ; Tiansheng SUN ; Dasheng TIAN ; Zheng WANG ; Bing WANG ; Linfeng WANG ; Qingde WANG ; Qinghe WANG ; Lan WEI ; Jigong WU ; Baoshan XU ; Youjia XU ; Guoyong YIN ; Jinglong YAN ; Feng YAN ; Cao YANG ; Huilin YANG ; Qiang YANG ; Bin ZHAO ; Jie ZHAO ; Yue ZHU ; Jianguo ZHANG ; Wenzhi ZHANG ; Zhongmin ZHANG ; Zhaomin ZHENG ; Yan ZENG ; Baorong HE ; Wei MEI
Chinese Journal of Trauma 2025;41(7):613-626
Vertebral refracture following percutaneous vertebral augmentation (PVA) is commonly seen in elderly patients with osteoporotic thoracolumbar compression fractures (OTLCF). It can lead to recurrent pain, loss of vertebral height, progression of kyphosis, and even neurological dysfunction, significantly impairing patients′ quality of life. Current diagnosis and treatment face multiple challenges, including high misdiagnosis rate, difficulty in choosing between surgical and non-surgical treatment options, lack of standardized surgical protocols, interference from intralesional bone cement during procedures, inadequate stability of internal fixation in osteoporotic bone, and suboptimal compliance of anti-osteoporotic therapy. Establishing a standardized diagnostic and therapeutic framework is urgently needed. To standardize the management process and improve outcomes for vertebral refractures after PVA in elderly OTLCF patients, Spinal Trauma Group of the Orthopedic Branch of Chinese Medical Doctor Association organized experts in the field to develop Guideline for the diagnosis and treatment of vertebral refracture after percutaneous vertebral augmentation in elderly patients with osteoporotic thoracolumbar compression fractures ( version 2025), based on current literature and clinical experience, and adhering to principles of scientific rigor and clinical applicability. A total of 11 recommendations were proposed, encompassing diagnosis, treatment, and rehabilitation of vertebral refracture after PVA in elderly patients with OTLCF, aiming to provide a foundation for a standardized management.
10.Study on accumulation of polysaccharide and steroid components in Polyporus umbellatus infected by Armillaria spp.
Ming-shu YANG ; Yi-fei YIN ; Juan CHEN ; Bing LI ; Meng-yan HOU ; Chun-yan LENG ; Yong-mei XING ; Shun-xing GUO
Acta Pharmaceutica Sinica 2025;60(1):232-238
In view of the few studies on the influence of


Result Analysis
Print
Save
E-mail